US · Healthcare · Drug Manufacturers - General
EPS came in at 0.89 against a street estimate of 0.81 — a beat of 9.9%.
Analysts rate Novo Nordisk A/S a hold (3 buy, 10 hold, 1 sell out of 14) with an average price target of $45.23.
| Fund | Stake |
|---|---|
| Dodge & Cox | 0.46% |
| Loomis, Sayles & Company LP | 0.42% |
| Franklin Templeton Inc | 0.30% |
| T. Rowe Price Associates, Inc. | 0.27% |
| Morgan Stanley - Brokerage Accounts | 0.26% |
| Bank of America Corp | 0.25% |
| Capital Research & Mgmt Co - Division 3 | 0.22% |
| Folketrygdfondet | 0.22% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 OTHER NOTABLE POINTS • Novo Nordisk disclosed an insider share transaction dated November 5, 2026. • Martin Holst Lange, Executive Vice President, R | 2026-11-05 |
| Quarterly results (6-K) · Q3 2026 HEADLINE NUMBERS • Q3 2026 net sales were DKK 79,195 million, up 4% at constant exchange rates (CER). • Q3 adjusted operating profit was DKK 31,720 | 2026-11-04 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Novo Nordisk repurchased 1,440,000 B shares between 26 October and 2 November 2026. • The shares were repurchased for a total tra | 2026-11-03 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Novo Nordisk repurchased 1,200,000 B shares between 19 and 23 October 2026 for DKK 312,323,798. • The shares were bought at an av | 2026-10-26 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Novo Nordisk repurchased 1,225,000 B shares from 12–16 October 2026 for DKK 316,147,881. • The shares were bought at average pric | 2026-10-19 |
| Current report (6-K) · Q4 2023 HEADLINE NUMBERS • Novo Nordisk repurchased 1,245,000 B shares between 5 October and 9 October 2026 for a total of DKK 311,605,554. • The shares wer | 2026-10-13 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Novo Nordisk repurchased 1,225,000 B shares between 28 September and 2 October 2026. • The shares were bought for a total of DKK | 2026-10-06 |
| Current report (6-K) · Q4 2026 HEADLINE NUMBERS • Novo Nordisk said the US FDA review of denecimig for haemophilia A remains ongoing, with no new timeline for regulatory action. • | 2026-10-05 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.58 / share ex-date Aug 17, 2026 · pay Aug 25, 2026 | 2026-08-17 |
| Dividend | $1.27 / share ex-date Mar 30, 2026 · pay Apr 8, 2026 | 2026-03-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Novo Nordisk A/S — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.